cvet-20200630
falseQ22020000175283612/31112,826,098689484250,000250,000250,000250,000250,000250,000112,674,657112,674,657111,620,507111,620,50700017528362020-01-012020-06-30xbrli:shares00017528362020-08-07iso4217:USD00017528362020-06-3000017528362019-12-31iso4217:USDxbrli:shares00017528362020-04-012020-06-3000017528362019-04-012019-06-3000017528362018-12-302019-06-300001752836us-gaap:CommonStockMember2020-03-310001752836us-gaap:AdditionalPaidInCapitalMember2020-03-310001752836us-gaap:RetainedEarningsMember2020-03-310001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100017528362020-03-310001752836us-gaap:RetainedEarningsMember2020-04-012020-06-300001752836us-gaap:CommonStockMember2020-04-012020-06-300001752836us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001752836us-gaap:CommonStockMember2020-06-300001752836us-gaap:AdditionalPaidInCapitalMember2020-06-300001752836us-gaap:RetainedEarningsMember2020-06-300001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001752836us-gaap:CommonStockMember2019-12-310001752836us-gaap:AdditionalPaidInCapitalMember2019-12-310001752836us-gaap:RetainedEarningsMember2019-12-310001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001752836us-gaap:RetainedEarningsMember2020-01-012020-06-300001752836us-gaap:CommonStockMember2020-01-012020-06-300001752836us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001752836us-gaap:CommonStockMember2019-03-310001752836us-gaap:AdditionalPaidInCapitalMember2019-03-310001752836us-gaap:RetainedEarningsMember2019-03-310001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001752836cvet:NetParentInvestmentMember2019-03-3100017528362019-03-310001752836us-gaap:RetainedEarningsMember2019-04-012019-06-300001752836cvet:NetParentInvestmentMember2019-04-012019-06-300001752836us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300001752836us-gaap:CommonStockMember2019-04-012019-06-300001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001752836us-gaap:CommonStockMember2019-06-300001752836us-gaap:AdditionalPaidInCapitalMember2019-06-300001752836us-gaap:RetainedEarningsMember2019-06-300001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001752836cvet:NetParentInvestmentMember2019-06-3000017528362019-06-300001752836us-gaap:CommonStockMember2018-12-290001752836us-gaap:AdditionalPaidInCapitalMember2018-12-290001752836us-gaap:RetainedEarningsMember2018-12-290001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-290001752836cvet:NetParentInvestmentMember2018-12-2900017528362018-12-290001752836us-gaap:RetainedEarningsMember2018-12-302019-06-300001752836cvet:NetParentInvestmentMember2018-12-302019-06-300001752836us-gaap:AdditionalPaidInCapitalMember2018-12-302019-06-300001752836us-gaap:CommonStockMember2018-12-302019-06-300001752836us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-302019-06-300001752836us-gaap:SeriesAPreferredStockMemberus-gaap:PrivatePlacementMember2020-04-302020-04-300001752836cvet:ScilAnimalCareBusinessMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-04-010001752836cvet:DistrivetMember2020-04-302020-04-300001752836us-gaap:SubsequentEventMembercvet:DistrivetMembersrt:ScenarioForecastMember2021-04-302021-04-30xbrli:pure0001752836cvet:DistrivetMember2020-04-3000017528362020-01-130001752836cvet:DistrivetMembercvet:InvestmentsandOtherMember2020-06-300001752836cvet:OtherNetMembercvet:DistrivetMember2020-01-012020-06-300001752836cvet:OtherNetMembercvet:DistrivetMember2020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SupplyChainMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SoftwareSolutionsMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:PrescriptionManagementMember2020-04-012020-06-300001752836cvet:NorthAmericaSegmentMemberus-gaap:MaterialReconcilingItemsMember2020-04-012020-06-300001752836cvet:NorthAmericaSegmentMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:SupplyChainMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMembercvet:EuropeSegmentMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:PrescriptionManagementMember2020-04-012020-06-300001752836cvet:EuropeSegmentMemberus-gaap:MaterialReconcilingItemsMember2020-04-012020-06-300001752836cvet:EuropeSegmentMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SupplyChainMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SoftwareSolutionsMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:PrescriptionManagementMember2020-04-012020-06-300001752836cvet:AsiaPacificandEmergingMarketsMemberus-gaap:MaterialReconcilingItemsMember2020-04-012020-06-300001752836cvet:AsiaPacificandEmergingMarketsMember2020-04-012020-06-300001752836srt:GeographyEliminationsMembercvet:SupplyChainMember2020-04-012020-06-300001752836cvet:SoftwareSolutionsMembersrt:GeographyEliminationsMember2020-04-012020-06-300001752836srt:GeographyEliminationsMembercvet:PrescriptionManagementMember2020-04-012020-06-300001752836srt:GeographyEliminationsMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:SupplyChainMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:PrescriptionManagementMember2020-04-012020-06-300001752836us-gaap:MaterialReconcilingItemsMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SupplyChainMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SoftwareSolutionsMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:PrescriptionManagementMember2019-04-012019-06-300001752836cvet:NorthAmericaSegmentMemberus-gaap:MaterialReconcilingItemsMember2019-04-012019-06-300001752836cvet:NorthAmericaSegmentMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:SupplyChainMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMembercvet:EuropeSegmentMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:PrescriptionManagementMember2019-04-012019-06-300001752836cvet:EuropeSegmentMemberus-gaap:MaterialReconcilingItemsMember2019-04-012019-06-300001752836cvet:EuropeSegmentMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SupplyChainMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SoftwareSolutionsMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:PrescriptionManagementMember2019-04-012019-06-300001752836cvet:AsiaPacificandEmergingMarketsMemberus-gaap:MaterialReconcilingItemsMember2019-04-012019-06-300001752836cvet:AsiaPacificandEmergingMarketsMember2019-04-012019-06-300001752836srt:GeographyEliminationsMembercvet:SupplyChainMember2019-04-012019-06-300001752836cvet:SoftwareSolutionsMembersrt:GeographyEliminationsMember2019-04-012019-06-300001752836srt:GeographyEliminationsMembercvet:PrescriptionManagementMember2019-04-012019-06-300001752836srt:GeographyEliminationsMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:SupplyChainMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:PrescriptionManagementMember2019-04-012019-06-300001752836us-gaap:MaterialReconcilingItemsMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SupplyChainMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SoftwareSolutionsMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:PrescriptionManagementMember2020-01-012020-06-300001752836cvet:NorthAmericaSegmentMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-06-300001752836cvet:NorthAmericaSegmentMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:SupplyChainMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMembercvet:EuropeSegmentMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:PrescriptionManagementMember2020-01-012020-06-300001752836cvet:EuropeSegmentMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-06-300001752836cvet:EuropeSegmentMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SupplyChainMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SoftwareSolutionsMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:PrescriptionManagementMember2020-01-012020-06-300001752836cvet:AsiaPacificandEmergingMarketsMemberus-gaap:MaterialReconcilingItemsMember2020-01-012020-06-300001752836cvet:AsiaPacificandEmergingMarketsMember2020-01-012020-06-300001752836srt:GeographyEliminationsMembercvet:SupplyChainMember2020-01-012020-06-300001752836cvet:SoftwareSolutionsMembersrt:GeographyEliminationsMember2020-01-012020-06-300001752836srt:GeographyEliminationsMembercvet:PrescriptionManagementMember2020-01-012020-06-300001752836srt:GeographyEliminationsMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:SupplyChainMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:PrescriptionManagementMember2020-01-012020-06-300001752836us-gaap:MaterialReconcilingItemsMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SupplyChainMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:SoftwareSolutionsMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMembercvet:PrescriptionManagementMember2018-12-302019-06-300001752836cvet:NorthAmericaSegmentMemberus-gaap:MaterialReconcilingItemsMember2018-12-302019-06-300001752836cvet:NorthAmericaSegmentMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:SupplyChainMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMembercvet:EuropeSegmentMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMembercvet:PrescriptionManagementMember2018-12-302019-06-300001752836cvet:EuropeSegmentMemberus-gaap:MaterialReconcilingItemsMember2018-12-302019-06-300001752836cvet:EuropeSegmentMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SupplyChainMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:SoftwareSolutionsMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMembercvet:PrescriptionManagementMember2018-12-302019-06-300001752836cvet:AsiaPacificandEmergingMarketsMemberus-gaap:MaterialReconcilingItemsMember2018-12-302019-06-300001752836cvet:AsiaPacificandEmergingMarketsMember2018-12-302019-06-300001752836srt:GeographyEliminationsMembercvet:SupplyChainMember2018-12-302019-06-300001752836cvet:SoftwareSolutionsMembersrt:GeographyEliminationsMember2018-12-302019-06-300001752836srt:GeographyEliminationsMembercvet:PrescriptionManagementMember2018-12-302019-06-300001752836srt:GeographyEliminationsMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:SupplyChainMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:SoftwareSolutionsMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:PrescriptionManagementMember2018-12-302019-06-300001752836us-gaap:MaterialReconcilingItemsMember2018-12-302019-06-300001752836srt:OfficeBuildingMemberstpr:AZ2020-01-012020-03-310001752836srt:OfficeBuildingMemberstpr:AZ2020-03-310001752836us-gaap:CostOfSalesMember2020-04-012020-06-300001752836us-gaap:CostOfSalesMember2019-04-012019-06-300001752836us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-300001752836us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-04-012019-06-300001752836us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2020-06-300001752836us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2019-12-310001752836srt:ScenarioForecastMember2021-01-012021-03-310001752836cvet:TermLoanPayableDueFebruary2024Memberus-gaap:NotesPayableToBanksMember2020-06-300001752836cvet:TermLoanPayableDueFebruary2024Memberus-gaap:NotesPayableToBanksMember2019-12-310001752836us-gaap:NotesPayableToBanksMembercvet:CollateralizedLoanPayablewithBalloonPaymentatMaturityDueMarch2023Member2020-06-300001752836us-gaap:NotesPayableToBanksMembercvet:CollateralizedLoanPayablewithBalloonPaymentatMaturityDueMarch2023Member2019-12-310001752836cvet:FinanceLeaseObligationsMember2020-06-300001752836cvet:FinanceLeaseObligationsMember2019-12-310001752836cvet:SyndicatedCreditAgreement2019Memberus-gaap:LineOfCreditMember2020-02-290001752836cvet:SyndicatedCreditAgreement2019Memberus-gaap:LineOfCreditMember2020-06-3000017528362020-04-102020-04-100001752836us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2019-12-310001752836us-gaap:CashFlowHedgingMembersrt:MinimumMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-06-300001752836us-gaap:CashFlowHedgingMembersrt:MaximumMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMember2020-06-300001752836us-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2020-06-300001752836us-gaap:CashFlowHedgingMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2019-12-310001752836us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2020-04-012020-06-300001752836us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestExpenseMemberus-gaap:InterestRateSwapMember2020-01-012020-06-300001752836us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2020-06-300001752836us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2019-12-310001752836us-gaap:PutOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-06-300001752836us-gaap:PutOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001752836us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-06-300001752836us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-31cvet:swap00017528362020-02-290001752836srt:ScenarioForecastMember2020-12-3100017528362018-12-302019-12-310001752836cvet:CDRVFCHoldingsL.P.Memberus-gaap:SeriesAPreferredStockMembercvet:InvestmentAgreementMemberus-gaap:PrivatePlacementMember2020-05-190001752836cvet:CDRVFCHoldingsL.P.Memberus-gaap:SeriesAPreferredStockMembercvet:InvestmentAgreementMemberus-gaap:PrivatePlacementMember2020-05-192020-05-190001752836cvet:CDRVFCHoldingsL.P.Memberus-gaap:SeriesAPreferredStockMembercvet:InvestmentAgreementMemberus-gaap:PrivatePlacementMember2020-04-302020-04-300001752836cvet:CDRVFCHoldingsL.P.Member2020-04-30cvet:Designees0001752836us-gaap:SeriesAPreferredStockMember2020-01-012020-06-30cvet:numberOfAnnualPeriods0001752836us-gaap:SeriesAPreferredStockMember2020-06-30cvet:numberOfTradingDayscvet:consecutiveTradingDays0001752836us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-290001752836us-gaap:AccumulatedTranslationAdjustmentMember2018-12-290001752836us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-302019-12-310001752836us-gaap:AccumulatedTranslationAdjustmentMember2018-12-302019-12-310001752836us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310001752836us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001752836us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-06-300001752836us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-06-300001752836us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300001752836us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300001752836us-gaap:PerformanceSharesMember2020-01-012020-06-300001752836us-gaap:PerformanceSharesMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMember2020-04-012020-06-300001752836us-gaap:CorporateNonSegmentMember2020-04-012020-06-300001752836us-gaap:IntersegmentEliminationMember2020-04-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMember2020-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMember2020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMember2020-06-300001752836us-gaap:CorporateNonSegmentMember2020-06-300001752836us-gaap:IntersegmentEliminationMember2020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMember2019-04-012019-06-300001752836us-gaap:CorporateNonSegmentMember2019-04-012019-06-300001752836us-gaap:IntersegmentEliminationMember2019-04-012019-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMember2019-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMember2019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMember2019-06-300001752836us-gaap:CorporateNonSegmentMember2019-06-300001752836us-gaap:IntersegmentEliminationMember2019-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMember2020-01-012020-06-300001752836us-gaap:CorporateNonSegmentMember2020-01-012020-06-300001752836us-gaap:IntersegmentEliminationMember2020-01-012020-06-300001752836us-gaap:OperatingSegmentsMembercvet:NorthAmericaSegmentMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:EuropeSegmentMember2018-12-302019-06-300001752836us-gaap:OperatingSegmentsMembercvet:AsiaPacificandEmergingMarketsMember2018-12-302019-06-300001752836us-gaap:CorporateNonSegmentMember2018-12-302019-06-300001752836us-gaap:IntersegmentEliminationMember2018-12-302019-06-30



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended June 30, 2020
or
Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from ____________ to _____________
Commission File Number: 001-38794
https://cdn.kscope.io/80d87aa8b26475e4b538de3f87d6c717-cvet-20200630_g1.gif
COVETRUS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware
83-1448706
(State or other jurisdiction of
incorporation)
(I.R.S. Employer
Identification No.)
7 Custom House Street
Portland, ME 04101
Tel: (888) 280-2221

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

        Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.01 per shareCVETNasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated FilerAccelerated Filer
Non-accelerated FilerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
No
The registrant had 112,826,098 shares of common stock outstanding as of August 7, 2020.




TABLE OF CONTENTS
Page

2

Table of Contents


PART I

Item 1. Condensed Consolidated Financial Statements

COVETRUS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except share amounts)
June 30,
2020
December 31,
2019
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents$414  $130  
Accounts receivable, net of allowance of $6 and $8
470  426  
Inventories, net484  636  
Other receivables75  67  
Prepaid expenses and other41  30  
Assets held for sale   51  
Total current assets1,484  1,340  
Non-current assets:
Property and equipment, net of accumulated depreciation of $94 and $84
102  93  
Operating lease right-of-use assets, net (Note 5)127  84  
Goodwill1,154  1,154  
Other intangibles, net (Note 6)572  643  
Investments and other (Note 3)87  47  
Total assets$3,526  $3,361  
LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable$429  $520  
Current maturities of long-term debt and other borrowings (Note 7)31  62  
Accrued payroll and related liabilities50  44  
Accrued taxes48  18  
Other current liabilities162  164  
Liabilities held for sale   21  
Total current liabilities720  829  
Non-current liabilities:
Long-term debt and other borrowings, net (Note 7)1,095  1,125  
Deferred taxes41  47  
Other liabilities141  94  
Total liabilities1,997  2,095  
Commitments and contingencies (Note 10)
Mezzanine equity:
Redeemable non-controlling interests (Note 11)9  10  
Redeemable series A convertible preferred stock, $0.01 par value, $1,000 per share liquidation preference, 250,000 shares authorized, issued, and outstanding as of June 30, 2020 (Note 12)
244    
Shareholders' equity:
Common stock, $0.01 par value per share, 675,000,000 shares authorized; 112,674,657 shares issued and outstanding as of June 30, 2020; 111,620,507 shares issued and outstanding as of December 31, 2019
1  1  
Accumulated other comprehensive loss (Note 13)(107) (86) 
Additional paid-in capital2,404  2,381  
Accumulated deficit(1,022) (1,040) 
Total shareholders’ equity1,276  1,256  
Total liabilities, mezzanine equity, and shareholders’ equity$3,526  $3,361  
See notes to condensed consolidated financial statements.
3

Table of Contents

COVETRUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts) (Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Net sales (Note 4)$1,026  $1,009  $2,091  $1,950  
Cost of sales834  816  1,696  1,580  
Gross profit192  193  395  370  
Operating expenses:
Selling, general and administrative196  198  419  384  
Operating loss(4) (5) (24) (14) 
Other income (expense):
Interest income1  2  1  3  
Interest expense(14) (15) (28) (26) 
Other, net (Note 3)76  13  75  15  
Income (loss) before taxes and equity in earnings of affiliates59  (5) 24  (22) 
Income tax expense (Note 14)(6) (5) (4) (1) 
Equity in net earnings of affiliates (Note 3)1    1    
Net income (loss)54  (10) 21  (23) 
Less: net income attributable to redeemable non-controlling interests    (1)   
Net income (loss) attributable to Covetrus$54  $(10) $20  $(23) 
Earnings (loss) per share attributable to Covetrus: (Note 15)
Basic$0.40  $(0.09) $0.15  $(0.22) 
Diluted$0.40  $(0.09) $0.15  $(0.22) 
Weighted-average common shares outstanding:
Basic112112112103
Diluted113112113103

See notes to condensed consolidated financial statements.
4

Table of Contents

COVETRUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In millions) (Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Net income (loss)$54  $(10) $21  $(23) 
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss) 6  4  (16) 5  
Unrealized gain (loss) on derivative instruments1    (7)   
Total other comprehensive income (loss)7  4  (23) 5  
 Comprehensive income (loss)61  (6) (2) (18) 
Comprehensive (income) loss attributable to redeemable non-controlling interests:
Net income    (1)   
Foreign currency translation (gain) loss    (2) 1  
Comprehensive income attributable to redeemable non-controlling interests    (3) 1  
Comprehensive income (loss) attributable to Covetrus$61  $(6) $(5) $(17) 
See notes to condensed consolidated financial statements.
5

Table of Contents

COVETRUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(In millions, except share amounts) (Unaudited)
Three Months Ended June 30, 2020
Common StockAdditional
Paid-in
Capital
Accumulated DeficitAccumulated Other Comprehensive LossTotal Shareholders' Equity
SharesAmount
Balance at March 31, 2020111,854,439  $1  $2,390  $(1,074) $(116) $1,201  
Net income attributable to Covetrus—  —  —  54  —  54  
Issuance of shares in connection with share-based compensation plans820,218  —  4  —  —  4  
Share-based compensation—  —  10  —  —  10  
Series A preferred stock cash dividend—  —  —  (2) —  (2) 
Other comprehensive income—  —  —  —  9  9  
Balance at June 30, 2020112,674,657  $1  $2,404  $(1,022) $(107) $1,276  
Six Months Ended June 30, 2020
Common StockAdditional
Paid-in
Capital
Accumulated DeficitAccumulated Other Comprehensive LossTotal Shareholders' Equity
SharesAmount
Balance at December 31, 2019111,620,507  $1  $2,381  $(1,040) $(86) $1,256  
Net income attributable to Covetrus—  —  —  20  —  20  
Issuance of shares in connection with share-based compensation plans1,054,150  —  4  —  —  4  
Share-based compensation—  —  19  —  —  19  
Series A preferred stock cash dividend—  —  —  (2) —  (2) 
Other comprehensive loss—  —  —  —  (21) (21) 
Balance at June 30, 2020112,674,657  $1  $2,404  $(1,022) $(107) $1,276  

6

Table of Contents

COVETRUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(In millions, except share amounts) (Unaudited) (Continued)
Three Months Ended June 30, 2019
Common StockAdditional
Paid-in
Capital
Accumulated DeficitAccumulated Other Comprehensive LossNet Former Parent InvestmentTotal Shareholders' Equity
SharesAmount
Balance at March 31, 2019111,576,343  $1  $2,395  $(21) $(81) $  $2,294  
Net (loss) income attributable to Covetrus—  —  —  (12) —  2  (10) 
Dividend to Former Parent—  —  (21) —  —    (21) 
Shares held in escrow expected to be canceled—  —  (30) —  —  —  (30) 
Net decrease in Former Parent investment—  —  —  —  —  (2) (2) 
Issuance of shares in connection with share-based compensation plans356,148  —  2  —  —  —  2  
Share-based compensation—  —  10  —  —  —  10  
Other comprehensive income—  —  —  —  4  —  4  
Balance at June 30, 2019111,932,491  $1  $2,356  $(33) $(77) $  $2,247  
Six Months Ended June 30, 2019
Common StockAdditional
Paid-in
Capital
Accumulated DeficitAccumulated Other Comprehensive LossNet Former Parent InvestmentTotal Shareholders' Equity
SharesAmount
Balance at December 29, 2018  $  $  $  $(82) $1,576  $1,494  
Net (loss) income attributable to Covetrus (a)
—  —  —  (33) —  10  (23) 
Dividend to Former Parent—  —  (21) —  —  (1,153) (1,174) 
Issuance of shares at Separation (including Share Sale investors)71,693,426  1  608  —  —  (609)   
Issuance of shares in connection with the Acquisition39,742,089  —  1,772  —  —  —  1,772  
Shares held in escrow expected to be canceled—  —  (30) —  —  —  (30) 
Net increase in Former Parent investment—  —  —  —  —  176  176  
Issuance of shares in connection with share-based compensation plans496,976  —  2  —  —  —  2  
Share-based compensation—  —  25  —  —  —  25  
Other comprehensive income—  —  —  —  5  —  5  
Balance at June 30, 2019111,932,491  $1  $2,356  $(33) $(77) $  $2,247  
(a) Net income earned from January 1, 2019 through February 7, 2019 is attributed to the Former Parent as it was the sole shareholder prior to February 7, 2019.
See notes to condensed consolidated financial statements.

7

Table of Contents

COVETRUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions) (Unaudited)
Six Months Ended June 30,
20202019
Cash flows from operating activities:
Net income (loss)$21  $(23) 
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization82  71  
Amortization of right-of-use assets12  10  
Gain on divestiture of a business(73)   
Share-based compensation expense19  25  
Benefit for deferred income taxes(2) (9) 
Gain on affiliate investment  (11) 
Amortization of debt issuance costs3  3  
Other(2)   
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net(56) (13) 
Inventories, net130  21  
Other assets and liabilities(14) (77) 
Accounts payable and accrued expenses(66) 6  
Net cash provided by operating activities54  3  
Cash flows from investing activities:
Purchases of property and equipment(24) (21) 
Payments related to equity investments and business acquisitions, net of cash acquired(13) (25) 
Proceeds from divestiture of a business, net104    
Proceeds from sale of property and equipment4  1  
Net cash provided by (used for) investing activities71  (45) 
Cash flows from financing activities:
Proceeds from revolving credit facility190    
Repayment of revolving credit facility(190)   
Proceeds from issuance of debt  1,220  
Principal payments of debt(62) (43) 
Debt issuance and amendment costs(5) (24) 
Dividend paid to Former Parent  (1,174) 
Issuance of common shares in connection with share-based compensation plans4  3  
Net transfers from Former Parent  165  
Proceeds from issuance of Series A preferred stock250    
Series A preferred stock issuance costs(6)   
Series A preferred stock dividend(2)   
Acquisition payment(17)   
Acquisitions of non-controlling interests in subsidiaries  (74) 
Net cash provided by financing activities162  73  
Effect of exchange rate changes on cash and cash equivalents(3) 1  
Net change in cash and cash equivalents284  32  
Cash and cash equivalents, beginning of period130  23  
Cash and cash equivalents, end of period$414  $55  
8

Table of Contents

COVETRUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions) (Unaudited) (Continued)
Six Months Ended June 30,
20202019
Supplemental disclosure of cash paid for:
Interest$23  $22  
Income taxes$10  $10  
Amounts included in the measurement of operating lease liabilities$13  $12  
Supplemental disclosures of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities$57  $71  
Deconsolidation of a subsidiary (Note 3)$15  $  
See notes to condensed consolidated financial statements.
9

Table of Contents
COVETRUS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions) (Unaudited)

1. Business Overview and Significant Accounting Policies

Business

Covetrus, Inc. (“Covetrus,” “Company,” “we,” “our,” “us,” or “ourselves”) is a global animal-health technology and services company dedicated to supporting the companion, equine, and large-animal veterinary markets. On February 7, 2019, Covetrus became an independent company through the consummation of the spin-off by Henry Schein (“Former Parent”) of its animal-health business (“Animal Health Business”) and the completion of its acquisition of Direct Vet Marketing, Inc. (d/b/a Vets First Choice) (“Vets First Choice”). On February 8, 2019, Covetrus began trading on the Nasdaq Stock Market. Accordingly, results provided in accordance with generally accepted accounting principles in the United States of America (“GAAP”) reflect the operations of the Animal Health Business from January 1, 2019 to June 30, 2019 and Vets First Choice for the period from February 8, 2019 to June 30, 2019.

Basis of Presentation and Principles of Consolidation

The accompanying balance sheet as of December 31, 2019, which was derived from audited financial statements, and the unaudited condensed consolidated financial statements as of and for the six months ended June 30, 2020, have been prepared in accordance with applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. Pursuant to those rules and regulations, we omitted certain information and disclosures normally included in annual financial statements prepared in accordance with GAAP.

In our opinion, the accompanying condensed consolidated financial statements reflect all recurring adjustments and transactions necessary for a fair statement of our financial position, results of operations, and cash flows for the interim periods presented. Such operating results are not necessarily indicative of annual or future results. These condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (“Form 10-K”) filed with the SEC on March 3, 2020.

The accompanying unaudited condensed consolidated financial statements include the operations of the Company, as well as those of our wholly-owned and majority-owned subsidiaries from their respective dates of inception or acquisition. All significant intercompany transactions and balances were eliminated in consolidation. Investments in unconsolidated affiliates, which are 20% to 50.01% owned, or investments of less than 20% in which we could influence the operating or financial decisions, are accounted for under the equity method.

Certain prior period amounts were reclassified or rounded to conform to the presentation of the current period.

Redeemable Convertible Preferred Stock

We classify our redeemable convertible preferred stock as mezzanine equity on our condensed consolidated balance sheets because it is redeemable at the option of holders upon a change of control as defined in the Certificate of Designation, Preferences and Rights for the Series A Preferred Stock (the “Certificate of Designations”), which is considered an event outside of our control. We recorded redeemable convertible preferred stock at fair value upon issuance, net of issuance costs. Our redeemable convertible preferred stock is not currently redeemable, nor is it probable of redemption. If and when a change of control becomes probable, we will accrete the redeemable convertible preferred stock to redemption value.

Accounting Pronouncements

Adopted

As of January 1, 2019, we adopted Accounting Standards Codification Topic 326, Credit Losses (“Topic 326”) which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including accounts receivable. Topic 326 is effective for interim and annual reporting periods beginning after December 15, 2019 and is required to be adopted using the modified retrospective basis, with a cumulative-effect adjustment to Retained earnings (Accumulated deficit) as of the beginning of the first reporting period in which the guidance of Topic 326 is effective. The adoption of Topic 326 did not have a material impact on the results of our condensed consolidated financial statements.
10

Table of Contents
COVETRUS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions) (Unaudited)

To be Adopted

ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” removes specific technical exceptions to general principles found in Topic 740, items that often produce information that investors have a hard time understanding and simplifies the accounting for income taxes. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. We are evaluating the anticipated impact of this standard on our condensed consolidated financial statements as well as timing of adoption.

ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”). The standard is currently effective and upon adoption may be applied prospectively to contract modifications made on or before December 31, 2022. We are evaluating the impact of the LIBOR transition and this optional relief guidance on our condensed consolidated financial statements.

2. Novel Coronavirus Disease 2019 (“COVID-19”)

The COVID-19 pandemic has resulted in social distancing and other measures that were instituted in various localities around the world. These measures led to phased temporary closures of non-essential businesses throughout many of the regions in which we conduct operations. However, veterinary care has been deemed an essential business in most of these regions and we continue to deliver products and services to our customers and their animal-owner clients. In addition, most of our customers are generally able to continue their operations through new social distancing guidelines which, depending on local regulations, can include telehealth and animal curbside check-in and drop-off at clinics. As a result, through June 30, 2020, we experienced limited disruption to our results of operations from the COVID-19 pandemic. However, the COVID-19 pandemic has created volatility and unpredictability to our business, including shifts in timing and channel mix, reduced travel and entertainment expenses due to travel restrictions, as well as other changes.

We believe our allowance for credit losses related to our accounts receivable is adequate as of June 30, 2020, due to the essential nature of our customers' businesses, as noted above, as well as the historic behavior of our large customer base. As the COVID-19 pandemic continues, there could be an increase in the aging of our accounts receivable, however, we do not anticipate a significant increase in defaults for such accounts receivable.

During the first quarter ended March 31, 2020, we experienced a sustained decline in our share price and a resulting decrease in our market capitalization due to the overall macroeconomic effects of the COVID-19 pandemic. Due to this overall market decline and the uncertainty surrounding COVID-19, we concluded that a triggering event occurred and conducted an interim impairment review of our goodwill as of March 31, 2020. We tested for goodwill impairment by quantitatively comparing the fair value of our North America reporting unit (the only reporting unit currently bearing goodwill) to its carrying amount. Using the income-based approach, fair value exceeded the carrying amount as of March 31, 2020. We did not experience triggering events during the second quarter ended June 30, 2020.

We took the following actions to help ensure that our business has flexibility to mitigate potential effects from continued global economic pressure:

During the quarter ended March 31, 2020, we borrowed funds under our revolving line of credit to increase our cash position and provide flexibility. In May 2020, we used a portion of the $244 million in aggregate net proceeds from the issuance of our Series A Convertible Preferred Stock to repay borrowings under our revolving line of credit. See Note 7 - Long-term Debt and Other Borrowings, Net and Note 12 - Redeemable Series A Convertible Preferred Stock.
We reduced our non-critical, near-term planned capital expenditures.
We negotiated for extended payment terms on certain contracts.
We managed our inventory levels in line with expected demand.
We instituted cost containment measures including temporary executive, board, and other senior-level employee compensation reductions, employee furloughs in certain European countries, certain shift eliminations, a temporary hiring freeze, discretionary spending deferrals, deferred payroll taxes as available under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), and suspended our 401(k)-employer match.
11

Table of Contents
COVETRUS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions) (Unaudited)

Some of these actions have been eased alongside our improved business performance and the recovery in our end-market. For example, in July, we returned to pre-COVID-19 compensation levels and, in August, we expect to reinstate our 401(k)-employer match. Hiring for our business was strictly limited, especially in response to the COVID-19 pandemic; however, we are relaxing the restrictions we instituted as part of our temporary hiring freeze. We continue to monitor our business performance and intend to take a cautious, but balanced approach in managing our expenses in light of uncertainty created by the COVID-19 pandemic.

Risk and Uncertainties

The duration and severity of COVID-19-related potential disruptions and the actions we have taken, and may take in the future, in response thereto, involve risks and uncertainties, and it is not possible at this time to estimate the impact that COVID-19 could have on our business. The impact of COVID-19 on various business activities in affected countries could adversely affect our estimates, results of operations, and financial condition.

3. Divestiture and Equity Method Investment

Divestiture

On April 1, 2020, we completed the divestiture of our scil animal-care business (“scil”) to Heska Corporation for $110 million pursuant to an amended purchase agreement. The cash flow impact of the transaction is $104 million which represents gross proceeds, net of cash included in the sale.

The sale of scil resulted in a pre-tax gain of $73 million that was recognized during the three months ended June 30, 2020 and included in Other, net in our condensed consolidated statements of operation.

Equity Method Investment

On April 30, 2020, we completed the previously announced combination of our subsidiary, Spain Animal Health Solutions S.L.U. (“SAHS”), with Distrivet, S.A. to form a leading animal-health provider on the Iberian Peninsula. We contributed SAHS by means of a contribution in kind of all the shares of SAHS in exchange for the transfer of shares from shareholders of Distrivet, S.A. (“Distrivet Shareholders”). In addition, at closing, we made a payment of $11 million, and we are obligated to make an additional payment of $11 million on the one-year anniversary of the closing of the combination. As a result of these transactions, we now own 50.01% of the new company, called Distrivet, a Covetrus company (“Distrivet”).

Based on Distrivet's governance structure, we do not have power over key financial and operating decisions that are made in the ordinary course of business. Accordingly, our investment in Distrivet is accounted for under the equity method and Distrivet is considered a related party. See Note 17 - Related Party Transactions.

The Investment and Shareholders Agreement of Distrivet, S.A. (“Agreement”) executed on January 13, 2020, contains put and call options on the shares owned by the Distrivet Shareholders, representing up to 49.99%, that are exercisable at fair market value based on floor and ceiling prices tied to Earnings Before Interest, Taxes, Depreciation, and Amortization (“EBITDA”) multiples as specified in the Agreement. See Note 9 - Fair Value.

During the three months ended June 30, 2020, we deconsolidated SAHS, remeasured our retained investment initially at a fair value of $45 million, which was included in Investments and other in our condensed consolidated balance sheet, and recognized a gain of $1 million, which was included in Other, net in our condensed consolidated statements of operation. The fair value was measured using third-party valuation models and was determined using both the market approach and income approach, which includes discounted expected cash flows. As of June 30, 2020, the carrying amount of our investment in Distrivet was $47 million.

12

Table of Contents
COVETRUS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(In millions) (Unaudited)
4. Revenue from Contracts with Customers

Disaggregation of Revenue

The tables below present our revenue disaggregated by major product category and reportable segment.
Three Months Ended June 30, 2020
Supply Chain ServicesSoftware
Solutions
Prescription ManagementEliminationsTotal
North America$495  $19  $110  $(22) $602  
Europe342  2    (2) 342  
APAC & Emerging Markets83  2      85  
Eliminations(3)     —  (3) 
Total Net sales$917  $23  $110  $(24) $1,026  
Three Months Ended June 30, 2019
Supply Chain ServicesSoftware
Solutions
Prescription Management